Plumbline Life Sciences플럼라인생명과학

Plumbline Life Sciences shows a thin recent record: no annual financials, no valuation metrics, and a share price down 24% over the past year.

The company is a small Korean animal biotech developing DNA medicines for dogs and pigs, with some products approved in Korea, Australia and New Zealand. The data pack contains no annual or trailing financials, so revenue and profit trends cannot be assessed. The stock trades at ₩4,635 against a 52-week high of ₩6,190, with a market value of about ₩18.7B.

What stands out

• No annual financial statements or trailing twelve-month figures are included in the data, so profitability and cash flow cannot be judged.
• Valuation ratios such as P/E, P/B and EV/EBITDA are unavailable, so the stock cannot be compared on earnings with peers.
• The share price is down 24% over one year but flat over one and three months, and the 52-week low is listed as ₩0, which looks like a data gap.
• Recent filings are dominated by administrative items: delisting notices, trading halts, shareholder meeting notices and an annual report added in March 2026.
• A major sales or supply contract was filed on 3 April 2026, but the filing title gives no details on size or terms.
• Foreign ownership is 12.6% and unchanged over 60 days; 20-day net flows show retail investors only.

What to watch

• Whether the company resolves the delisting and trading halt filings, and what the filings say about its status on the KONEX market.
• Details of the April 2026 sales or supply contract, including value and counterparty, once they are available in the filings.
• Any future filing of full financial statements, since the current data gives no revenue or profit figures to check the business against.